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Abstract
Background: Men with localized prostate cancer often have unrealistic expectations. Practitioners are poor judges
of men’s preferences, contributing to preference misdiagnosis and unwarranted practice variation. Patient decision
aids (PtDAs) can support men with decisions about localized prostate cancer. This is a comparative case study of
two strategies for implementing PtDAs in clinical pathways for men with localized prostate cancer, evaluating (a)
PtDA use; (b) impact on men, practitioners, and health system outcomes; and (c) factors influencing sustained use.
Methods/design: Guided by the Knowledge to Action Framework, this comparative case study will be conducted
using administrative data, interviews, and surveys. Cases will be bound by geographic location (one hospital in
Ontario; province of Saskatchewan) and time. Eligible participants will be all men newly diagnosed with localized
prostate cancer, with outcomes assessed using administrative data and interviews. Nurses, urologists, radiation
oncologists, and managers will be surveyed and a smaller sample interviewed. Cases will be established for each
setting with findings compared across cases. Changes in the proportions of men given the PtDA over 2 years will
be determined from administrative data. Factors associated with receiving the PtDA will be explored using
multivariable logistic regression analysis. To assess the impact of the PtDA, outcomes will be described using mean
and standard deviation (men’s decisional conflict) and frequency and proportions (practitioners consulted, uptake of
treatment). To estimate the effect of the PtDA on these outcomes, adjusted mean differences and odds ratios will
be calculated using exploratory multivariable general linear regression and binary or multinomial logistic regression.
Factors influencing sustained PtDA use will be assessed using descriptive analysis of survey findings and thematic
analysis of interview transcripts.
Discussion: Determining how to embed PtDAs effectively within clinical pathways for men with localized prostate
cancer is essential. PtDAs have the potential to strengthen men’s active role in making prostate cancer decisions,
enhance uptake of shared decision-making by practitioners, and reduce practice variation. Our team of researchers
and knowledge users will use findings to improve current PtDA use and consider scaling-up implementation.
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Background
Although patient decision aids (PtDAs) are effective in-
terventions for translating evidence for patients [1], they
are not routinely used in clinical practice [2]. Our study
aims to close the gap between what is currently known
about PtDAs from research studies and what is done
with PtDAs when they are implemented in routine clin-
ical practice. Men with localized prostate cancer face a
difficult decision because there are four main options
(e.g., surgery, external radiation, brachytherapy, and ac-
tive surveillance) with different potential benefits and
harms. Given little evidence to indicate that one option
is better than another, the chosen option should be con-
sistent with men’s informed preferences based on weigh-
ing benefits and harms across options [3–5].
When asked to take an active role in making these dif-
ficult decisions, patients often experience decisional con-
flict and have unrealistic expectations [6–9]. Decisional
conflict is “personal uncertainty about which course of
action to take when choice among competing options
involves risk, regret, or challenge to personal life values”
[7–9]. Adults with unresolved decisional conflict are
more likely to delay decisions, feel regret, be dissatisfied,
and blame doctors for bad outcomes [10, 11]. Moreover,
without effective decision support, patients may be ex-
posed to more costly options without any better outcomes
[12, 13]. Studies in Canada and the USA found that urolo-
gists and radiation oncologists often provide unbalanced
information on options in favour of their own expertise,
and they are not able to correctly guess men’s preferences
[14, 15]. Practice variations in age-standardized rates of
surgery for prostate cancer are 32 to 57 % across Ontario,
Canada [16]. This variation may be unwarranted given
that the best option depends on men’s preferences [17].
For adults facing difficult decisions, providing a struc-
tured approach to decision-making such as PtDAs helps
empower individuals, resolves decisional conflict, and re-
duces unwarranted practice variation [13, 17]. PtDAs are
booklets and/or videos that provide balanced informa-
tion on options (benefits/harms), help clarify patients’
preferences, and guide patients making decisions with
their practitioner [18]. A systematic review of 115 trials
of PtDAs (including prostate cancer treatment) found
that patients exposed to PtDAs are more involved in de-
cision-making with improved knowledge, more realistic
expectations of outcomes, and enhanced agreement be-
tween options chosen and patients’ values [13, 19]. Despite
strong evidence, few PtDAs are used in clinical practice
[2]. In 17 implementation studies, factors interfering with
their use were healthcare professionals having inadequate
training, being indifferent about using them, lacking confi-
dence in their content, and being concerned about dis-
rupting workflows [2]. Only one implementation study in
England involved men with prostate cancer [20]. These
men had improved knowledge and values-choice agree-
ment, shifted rates from surgery to radiation, and rated
the PtDA positively. Staff said the PtDA was used by men
at home and off-loaded work in busy clinics. Other studies
have shown that few practitioners attempt to involve pa-
tients in decision-making and fewer adjust care to patients’
preferences [21], thus leading to a “silent misdiagnosis of
clients’ preferences,” a key determinant of health system
performance as a whole [22]. Hence, it is important to
study implementation of PtDAs to understand approaches
that increase sustained use and have positive impacts on
patient, practitioner, and health system outcomes.
In our previous research with 192 patients in an am-
bulatory oncology program, only half were offered treat-
ment choices and those offered choices were more likely
to have an active role in decision-making [23]. Patients
whose preferred role was different from their actual role
preferred more involvement. Next, we explored using
PtDAs for men with localized prostate cancer [24]. A team
of researchers and knowledge users appraised PtDAs
against the International Patient Decision Aid Standards
[25] to identify two higher quality PtDAs (one was booklet
only; one was booklet plus video). Interviews with prostate
cancer survivors, urologists, oncologists, and nurses rated
the PtDAs positively for plain language, helpful informa-
tion, and ability to share with family [24]. Men wanted
more information on sexual effects and brachytherapy.
Factors perceived to influence their use were men’s
preferred level of involvement, staff time to distribute,
practitioners’ own agenda, and practitioner/manager
buy-in. Since September 2010, the higher quality PtDA
with booklet and video from Health Dialog was inte-
grated into the clinical pathway for men diagnosed
with localized prostate cancer at The Ottawa Hospital.
In 2010, a key health goal of Saskatchewan was to imple-
ment a shared decision-making framework to engage
patients in decisions about their treatment options [26].
In May 2013, the prostate cancer surgical pathway in
Saskatchewan started using PtDAs with men having lo-
calized prostate cancer [27]. Implementation has not been
evaluated in either program and anecdotally, not all men
receive a PtDA.
Researchers on this team have also updated the Cochrane
review of PtDAs [13], the Cochrane review of interventions
for uptake of shared decision-making [28], and reviews on
shared decision-making training [29–31], PtDA imple-
mentation [2], and PtDA used with decision coaching
[32, 33]. None of the studies measured sustained the
use of PtDAs or factors influencing sustained use. A re-
cent study of PtDA implementation for patients with
cystic fibrosis in Canada revealed 85 and 92 % PtDA
usage at 1 and 2 years, respectively, but findings were
based on nurse reporting rather than more objective
administrative data [34].
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The overall aim of this comparative case study is to
evaluate two strategies for implementing PtDAs in clin-
ical pathways for men with localized prostate cancer by
measuring (a) the use of PtDA over a 2-year period after
implementation; (b) impact of the PtDA on men, practi-
tioners, and health system outcomes; and (c) factors in-
fluencing sustained use (or not) for each strategy.
Methods/design
Our comparative case study will use mixed methods and
will be guided by the Knowledge to Action Framework
[35, 36]. Following Yin’s approach, the cases will be bound
by location (prostate cancer clinical pathway at one hos-
pital in one provincial health system and the prostate can-
cer surgical pathway in another province) and time period
(2 years after PtDA implementation) [37]. The Knowledge
to Action framework focuses on specific implementation
factors essential for success in real world, naturalistic envi-
ronments [35, 36]. The Action Cycle was activated by a
problem identified by the knowledge users (e.g., men want
to be more involved in prostate cancer decisions), and the
knowledge solution is a PtDA. Then, we will identify inter-
ventions to overcome identified barriers. This proposed
implementation study is focused on the final phases of the
Framework: monitor use, evaluate outcomes, and measure
sustained use. Sustainability requires monitoring use for 2
or more years [38]. We obtained ethics approval at The
Ottawa Health Science Network Research Ethics Board
(#20150604-01H), the Saskatoon Health Region Research
Ethics Board (#BEH-15-382), Reginal Qu’Appelle Health
Region Research Ethics Board (REG-15-125), and the
University of Saskatchewan Behavioural Research Ethics
Board (BEH#15-382).
The setting for our study is prostate cancer healthcare
services that implemented PtDAs in the clinical pathways:
The Ottawa Hospital in Ontario (in 2010) and the Minis-
try of Health in the Province of Saskatchewan (in 2013).
These prostate cancer healthcare services have urologists
and radiation oncologists serving populations of about
1 million each. Annually, about 400 men have consulta-
tions for prostate cancer at The Ottawa Hospital Can-
cer Assessment Clinic and about 600 in Saskatchewan.
Within the clinical pathway, men diagnosed with local-
ized prostate cancer are asked to use the PtDA at home
in preparation for the consultation. Nurses, trained in
interprofessional shared decision-making [31], discuss
men’s questions prior to the physician consultation.
Participants for the interviews are men who have re-
ceived a diagnosis of localized prostate cancer (including
their partners) and received services at The Ottawa Hos-
pital or in Saskatchewan. Other stakeholder participants
who have varying levels of influence in the prostate can-
cer programs include urologists, radiation oncologists,
nurses, and managers.
Procedures focus on collecting clinical administrative
data (clinical databases, electronic/paper-based health re-
cords) and conducting a survey and interviews (Table 1).
Routinely collected administrative data sources will be
reviewed to identify men newly diagnosed with localized
prostate cancer for calendar years of 2011–2012 in Ottawa
and 2014–2015 in Saskatchewan. Data will be retrieved on
(a) their age, co-morbidities with severity, prostate cancer
characteristics; (b) practitioners’ documentation of the
decision-making consultation; (c) uptake of treatment or
surveillance; (d) whether given the PtDA or not; and (e)
level of decisional conflict (Table 2).
A survey will be sent to urologists (n = 8–10) per site,
radiation oncologists (n = 5-7), and nurses (n = 4–6) in
the prostate programs to assess their use of PtDA and
factors influencing use. Eligible participants will receive
a mailed package that will include a cover letter with the
study purpose and information on how the information
will be used and the survey with a stamped pre-addressed
envelope. To enhance response rates, Dillman’s approach
will be used with reminders at 2, 4, and 5 weeks [39].
Interviews will be conducted with a purposeful sample
of men given/not given the PtDA (and/or their partners),
nurses, managers, radiation oncologists, and urologists
in each program (Table 1). Men newly diagnosed with
prostate cancer during the last 3 years post-PtDA imple-
mentation will be contacted by a healthcare professional
from the circle of care or through the local prostate can-
cer support groups. Purposeful sampling will be used to
identify other stakeholders having varying levels of influ-
ence in the prostate cancer programs (e.g., nurses, urolo-
gists, radiation oncologists, and managers). Prospective
participants will be invited to participate in an interview
by (a) announcement of the study at staff meetings, (b)
hard copy posters on staff bulletin boards, and (c) email
to staff (Ottawa only). A letter explaining the study will
be provided to prospective participants, and written in-
formed consent will be obtained (Additional files 1 and 2).
For healthcare practitioners, a semi-structured interview
guide developed using the Knowledge to Action Frame-
work [35] will be used to explore perceptions of PtDAs,
factors influencing PtDA sustained use, interventions re-
quired to overcome remaining barriers, and concurrent
initiatives that may have influenced PtDA use. For men
given or not given a PtDA, a semi-structured interview
guide was developed to learn more about their experience
with how the decision was made to treat or monitor their
prostate cancer. All participants will be asked to complete
demographic questions.
Interventions will be identified to address barriers
interfering with the use of PtDAs if the prevalence of
use is found to be less than 80 %. If PtDA use is 80 % or
higher, strategies for monitoring sustained use with feed-
back mechanisms will be established [40]. Successful
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Table 1 Proposed study data collection elements and analysis
Outcome Participants Data source Analysis
Proportion given the PtDA Men with localized prostate cancer Clinical administrativea
data (~n = 1000)
Proportion with 95 % confidence intervals for each case study
Men’s outcomes: decisional conflict Men with localized prostate cancer Clinical administrativea
data (~n = 1000)
Linear regression (decisional conflict) to compare those who




and nurses in prostate programs
Mailed survey (~n = 40) Multivariable ordinal logistic regression analysis of practitioner’s
reported use of PtDA with factors reported in the survey as
covariates. Subgroup analysis will be done by types of
practitioner (e.g., urologists, radiation oncologists, nurses)
Health system outcomes: uptake
of treatment (including surveillance)
and practitioner consultations
All men with localized prostate cancer Clinical administrativea
data (~n = 1000)
Multinomial and binary logistic regression analysis of treatment
uptake and practitioner consultations with receipt of the PtDA
as main predictor, and adjusting for patient demographic and
clinical characteristics.
Factors influencing PtDA implementation Key stakeholders in each program Individual interviews
(~n = 30–40)
Thematic analysis guided by the Knowledge to Action Framework












implementation of evidence in clinical practice requires
tailored interventions based on identified barriers [41].
Instruments to be used have been found to be valid,
reliable, and have been previously been used in PtDA
studies. The four-item SURE test is used to screen for
decisional conflict to inform clinical practice [42–44]. It
has moderate reliability (Cronbach Alpha 0.65) and dis-
criminates between those who had/had not made a
choice. Factors influencing PtDA use by practitioners
will be measured using the 12-item Continuing Pro-
fessional Development Reaction Questionnaire (Cron-
bach Alpha 0.77-0.85) [45]. Potential environmental
barriers influencing PtDA use will be taken from a
Barriers Survey [46].
Outcomes are based on the Knowledge to Action
Framework [35]. After knowledge is implemented (e.g.,
Table 2 Data collection tool: prostate cancer PtDA implementation study
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PtDA), its uptake should be monitored to determine
how and to what extent it is used [35]. We plan to use
administrative data to measure the proportion of men
who were given the PtDA and qualitative interviews to
explore men’s use. The next phase of the Framework is
to measure the impact of knowledge use on outcomes
specific to patients, providers, and healthcare systems
[35]. We will measure the impact of PtDA use on men’s
decisional conflict using administrative data; practitioners’
and patients’ consultations using qualitative interviews;
and impact on healthcare systems using administrative
data to measure uptake of treatment and types of practi-
tioners consulted during decision-making. Measuring im-
pact of PtDA on these outcomes will ensure that PtDA
use is influencing quality indicators as observed in ran-
domized controlled trials without any unintended conse-
quences [13, 40]. Sustaining the use of the knowledge is
the last phase in the Action Cycle of this Framework
[35, 47]. Given that barriers can change with PtDA use
[46], we will assess barriers using a practitioner survey
and qualitative interviews.
Analysis
Two cases will be developed with a rich description of
the context and outcomes with comparisons within and
across the cases [37]. For PtDA use, the proportion of
men given the PtDA will be calculated for each site with
95 % confidence intervals (Table 1). We anticipate about
600 men diagnosed with localized prostate cancer over
2 years at The Ottawa Hospital Cancer Assessment Clinic
and 400 in the Provincial Prostate Pathway in Saskatch-
ewan. Using conservative estimates for proportions given
the PtDA of 50 and 90 % in Ottawa and Saskatchewan, re-
spectively, these sample sizes are adequate to estimate the
true proportions given the PtDA with margins of error
+4.0 % in Ottawa and +2.9 % in Saskatchewan using two-
sided 95 % confidence intervals. Characteristics and out-
comes of patients who did and did not receive the PtDA
will be described at each site using mean and standard
deviation for continuous variables, and frequencies and
proportions for categorical variables.
Factors associated with receiving the PtDA will be ex-
plored at each site and overall using multivariable logis-
tic regression analysis by entering patient characteristics
(e.g., age, co-morbidity, severity of disease, cancer char-
acteristics) as well as provider characteristics (e.g., sex,
years of experience, discipline). To explore differences in
the effect of these characteristics across the two sites,
site and interactions between the characteristics and site
will be included in the model. If the proportion using
the PtDA is 50 % in Ottawa and 90 % in Saskatchewan,
according to a commonly used rule of 10 events per in-
dependent variable, the maximum number of variables
that can be included in these analyses is 66; thus, we
have more than the required degrees of freedom avail-
able to fit our models. The extent of missing data will be
tabulated, and characteristics of those with and without
missing data will be compared. If more than 5 % missing
data is observed among predictors, the use of multiple
imputation will be explored. The analysis will account
for clustering by provider through the inclusion of ran-
dom intercepts for each provider. The model will be es-
timated using pseudo-likelihood or maximum likelihood
in SAS v9.3.
Outcomes between those given the PtDA and those
not given it will be described at each site using mean
and standard deviation (decisional conflict) and frequency
and proportions (uptake of treatment, type of practitioner
consulted). To estimate the effect of the PtDA on these
outcomes after accounting for potential confounders, we
will conduct exploratory multivariable general linear re-
gression and binary or multinomial logistic regression at
each site and overall. The analysis will adjust for patient
characteristics associated with the use of the PtDA, and
patient clinical and demographic characteristics poten-
tially associated with the outcomes. To explore differences
between the sites, we will include site and its interaction
with the receipt of the PtDA into the model. Results will
be expressed as adjusted mean differences and adjusted
odds ratios together with 95 % confidence intervals.
For impact on practitioner outcomes and sustained
use, we will identify remaining barriers influencing prac-
titioner PtDA use with the survey and interview data.
Audio-taped interviews will be transcribed verbatim and
analyzed qualitatively by two team members using the-
matic analysis. We expect to reach saturation by 12 to
15 interviews in each case study [48].
The study Timeline is 12 months: 3 months for start-
up; 5 months for collecting clinical administrative data,
conducting the survey, and interviewing; 2 months for
data cleaning/analysis; and 2 months for drafting case
studies and disseminating findings.
Dissemination plan
The knowledge users on the research team will dissem-
inate results within their organizations and through their
networks. As well, we plan to publish the results in open
access peer-reviewed journals and provide presentations
at relevant international and national oncology and im-
plementation science conferences. We plan to disseminate
a brief policy report and our research tools (in English/
French) through our networks and on research websites
(decisionaid.ohri.ca; www.ktcanada.ohri.ca; decision.chair-
e.fmed.ulaval.ca). This end of grant knowledge translation
plan has the potential to improve ongoing use of PtDA for
men with localized prostate cancer, highlight the impact
on various outcomes, and inform approaches for imple-
menting PtDAs in other programs.
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Discussion
Our deliverables are findings on the actual use of PtDAs
for men with localized prostate cancer using two differ-
ent implementation approaches in two different health-
care systems over a 2-year period. We will measure
outcomes on patients, practitioners, and the healthcare
system to ensure findings are consistent with benefits of
PtDAs reported in randomized controlled trials of PtDAs
without unintended consequences. Importantly, we will
also learn about strategies required to ensure sustained
use of PtDAs. In summary, deliverables include an ap-
proach for implementing PtDAs, ways to monitor their
use to provide feedback to knowledge users, and strategies
required to support their sustained use.
Our study results will advance knowledge about imple-
mentation of PtDA into clinical practice. These findings
can be used by knowledge users on our team for making
decisions about improving implementation of PtDAs
and scaling up their use with patients having prostate
cancer or other cancers. We anticipate that the implemen-
tation of PtDAs enhanced patient-centred care by increas-
ing patient involvement in health decisions, thereby
boosting public confidence in healthcare services [20] and
improving quality of life [49] to advance the Canadian
Cancer Society’s mission. Health policy documents in
Saskatchewan [50], Ontario [51], and in other countries
(e.g., USA, UK, Australia, Germany) call for a “patient
first” approach to healthcare that can be improved by
patients using PtDAs and making decisions with their
practitioner, thus, creating demand for evidence on
sustainable PtDA implementation approaches that our
study will provide.
Research team
Fundamental to our study is an integrated knowledge
translation approach [52] whereby knowledge users repre-
senting policy makers, practitioners, and a patient are col-
laborating as research team members. Knowledge users
helped define the research objectives and provided critical
feedback on our proposed study [53]. Engaging knowledge
users in meaningful ways during the proposal develop-
ment should maximize the likelihood of producing find-
ings of use to them and enhance uptake of our study
findings [54]. Knowledge users will be engaged in inter-
preting study findings and disseminating results.
Our proposed study will be managed from the Ottawa
Hospital Research Institute: a multidisciplinary research-
intensive environment with knowledge translation research
as one of its strategic priorities. Our research team is inter-
nationally recognized as a leader in PtDA’s development,
evaluation, and implementation. We have a highly pro-
ductive team of researchers, knowledge users, and trainees
with expertise in oncology, knowledge translation, health
services research, and health policy. Our team is in a
supportive research environment, has established collabo-
rations with necessary expertise to conduct the proposed
study, and can transfer findings to inform health policy
and services.
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